HLN — Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: GB
- Exchange: NYSE
- Employees: 24,561
- Website: https://www.haleon.com
Latest SEC filings for HLN
- 424B5 — 2026-08-13
- 424B5 — 2026-08-11
- 6-K — 2026-07-02
- 6-K — 2026-06-08
- 6-K — 2026-03-24
- 6-K — 2026-02-02
- 6-K — 2026-01-21
- 6-K — 2026-01-08
- 6-K — 2026-01-06
- 6-K — 2026-01-02
Latest HLN news
- — Haleon Launches ‘Haleon Health House,’ a One-Day Interactive Wellness Pop-Up in Toronto (GlobeNewswire Inc.)
- — Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market Does (The Motley Fool)
- — Only Excedrin Brings Digital Pet Nostalgia Back with a Headache You Can't Ignore (prnewswire.com)
- — Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors
- — Unilever on JP Morgan positive watch as Haleon faces caution
- — LCUT vs. HLN: Which Stock Is the Better Value Option?
Educational tool only — not investment advice.